Drug Profile
Research programme: injectable insulin formulations - Rezolute
Alternative Names: AB 102; insulin sustained-releaseLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator PR Pharmaceuticals
- Developer Rezolute
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 07 Dec 2017 AntriaBio is now called Rezolute
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (SC, Injection)
- 05 Jun 2017 AntriaBio plans a first-in-human, phase I trial to evaluate the safety, pharmacokinetics and time-action profile of single ascending doses of AB 101, for Type 1 diabetes mellitus in USA